Yang Philip, Iffrig Elizabeth, Harris Frank, Holder Andre L, Martin Greg S, Esper Annette M
Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Emory University and Grady Memorial Hospital, Atlanta, GA.
Department of Pediatrics, Emory University, Atlanta, GA.
Crit Care Explor. 2022 Oct 20;4(10):e0780. doi: 10.1097/CCE.0000000000000780. eCollection 2022 Oct.
The role of early, serial measurements of protein biomarkers in sepsis-induced acute respiratory distress syndrome (ARDS) is not clear.
To determine the differences in soluble receptor for advanced glycation end-products (sRAGEs), angiopoietin-2, and surfactant protein-D (SP-D) levels and their changes over time between sepsis patients with and without ARDS.
Prospective observational cohort study of adult patients admitted to the medical ICU at Grady Memorial Hospital within 72 hours of sepsis diagnosis.
Plasma sRAGE, angiopoietin-2, and SP-D levels were measured for 3 consecutive days after enrollment. The primary outcome was ARDS development, and the secondary outcome of 28-day mortality. The biomarker levels and their changes over time were compared between ARDS and non-ARDS patients and between nonsurvivors and survivors.
We enrolled 111 patients, and 21 patients (18.9%) developed ARDS. The three biomarker levels were not significantly different between ARDS and non-ARDS patients on all 3 days of measurement. Nonsurvivors had higher levels of all three biomarkers than did survivors on multiple days. The changes of the biomarker levels over time were not different between the outcome groups. Logistic regression analyses showed association between day 1 SP-D level and mortality (odds ratio, 1.52; 95% CI, 1.03-2.24; = 0.03), and generalized estimating equation analyses showed association between angiopoietin-2 levels and mortality (estimate 0.0002; se 0.0001; = 0.04).
Among critically ill patients with sepsis, sRAGE, angiopoietin-2, and SP-D levels were not significantly different between ARDS and non-ARDS patients but were higher in nonsurvivors compared with survivors. The trend toward higher levels of sRAGE and SP-D, but not of angiopoietin-2, in ARDS patients may indicate the importance of epithelial injury in sepsis-induced ARDS. Changes of the biomarker levels over time were not different between the outcome groups.
蛋白质生物标志物的早期连续测量在脓毒症诱导的急性呼吸窘迫综合征(ARDS)中的作用尚不清楚。
确定伴有和不伴有ARDS的脓毒症患者之间晚期糖基化终末产物可溶性受体(sRAGEs)、血管生成素-2和表面活性蛋白-D(SP-D)水平的差异及其随时间的变化。
设计、设置和参与者:对在脓毒症诊断后72小时内入住格雷迪纪念医院内科重症监护病房的成年患者进行前瞻性观察队列研究。
入组后连续3天测量血浆sRAGE、血管生成素-2和SP-D水平。主要结局是ARDS的发生,次要结局是28天死亡率。比较ARDS和非ARDS患者以及非幸存者和幸存者之间的生物标志物水平及其随时间的变化。
我们纳入了111名患者,21名患者(18.9%)发生了ARDS。在测量的所有3天中,ARDS和非ARDS患者的三种生物标志物水平无显著差异。在多个时间点,非幸存者的所有三种生物标志物水平均高于幸存者。结局组之间生物标志物水平随时间的变化无差异。逻辑回归分析显示第1天SP-D水平与死亡率之间存在关联(比值比,1.52;95%可信区间,1.03 - 2.24;P = 0.03),广义估计方程分析显示血管生成素-2水平与死亡率之间存在关联(估计值0.0002;标准误0.0001;P = 0.04)。
在患有脓毒症的危重症患者中,ARDS和非ARDS患者之间的sRAGE、血管生成素-2和SP-D水平无显著差异,但非幸存者的水平高于幸存者。ARDS患者中sRAGE和SP-D水平升高的趋势,而非血管生成素-2,可能表明上皮损伤在脓毒症诱导的ARDS中的重要性。结局组之间生物标志物水平随时间的变化无差异。